# OnCo record measurement-to-benefit-evidence (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/measurement-to-benefit-evidence/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "measurement-to-benefit-evidence" ;
  schema:name "Evidence from measurement to patient benefit"@en ;
  schema:description "A reliable measurement, a biological explanation and a useful treatment decision each need evidence. This map helps readers identify which part of a claim has actually been tested."@en ;
  schema:url <https://onco.cc/terms/measurement-to-benefit-evidence/> ;
  schema:dateModified "2026-11-10"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification>, <https://doi.org/10.1126/science.1233606>, <https://doi.org/10.1093/annonc/mdy263>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6938631/>, <https://pubmed.ncbi.nlm.nih.gov/30137196/>, <https://www.fda.gov/media/71195/download> ;
  onco:related <https://onco.cc/terms/antigen-expression-and-response/>, <https://onco.cc/terms/binding-site-barrier/>, <https://onco.cc/terms/antibody-internalization-trafficking/>, <https://onco.cc/terms/lysosomal-payload-egress/>, <https://onco.cc/terms/drug-target-engagement/>, <https://onco.cc/terms/experimental-versus-clinical-exposure/>, <https://onco.cc/terms/prognostic-versus-predictive-biomarkers/>, <https://onco.cc/terms/functional-variant-evidence/>, <https://onco.cc/terms/blood-cell-variants-liquid-biopsy/>, <https://onco.cc/terms/ctdna-shedding-negative-results/>, <https://onco.cc/terms/detection-versus-quantification/>, <https://onco.cc/terms/finite-molecule-sampling/>, <https://onco.cc/terms/tumor-informed-assay-design/>, <https://onco.cc/terms/biomarker-qualification-context/>, <https://onco.cc/terms/test-agreement-versus-accuracy/>, <https://onco.cc/terms/growth-rate-inhibition/>, <https://onco.cc/terms/cytostasis-versus-cell-death/>, <https://onco.cc/terms/on-target-drug-validation/>, <https://onco.cc/terms/model-context-of-use/>, <https://onco.cc/terms/confounding-by-indication/>, <https://onco.cc/terms/immortal-time-bias/>, <https://onco.cc/terms/target-trial-emulation/>, <https://onco.cc/terms/competing-risks/>, <https://onco.cc/terms/trial-population-transportability/>, <https://onco.cc/terms/biomarker-cutpoint-selection/>, <https://onco.cc/terms/decision-curve-net-benefit/>, <https://onco.cc/terms/inconclusive-and-negative-evidence/>, <https://onco.cc/terms/analytical-vs-clinical-validation/>, <https://onco.cc/terms/cancer-drivers-vs-actionable/> .
